PHP
NUVL

Parkman Healthcare Partners’s Nuvalent NUVL Stock Holding History

Parkman Healthcare Partners’s Portfolio NUVL Stock Details NUVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.02M Sell
88,078
-30,634
-26% -$3.12M 0.93% 38
2025
Q4 		$11.9M Sell
118,712
-1,478
-1% -$146K 1.14% 34
2025
Q3 		$10.4M Buy
120,190
+567
+0.5% +$44.8K 1.08% 34
2025
Q2 		$9.13M Buy
119,623
+9,635
+9% +$705K 1.05% 31
2025
Q1 		$7.8M Buy
109,988
+86,400
+366% +$6.76M 0.93% 39
2024
Q4 		$1.85M Buy
23,588
+188
+0.8% +$17.6K 0.25% 76
2024
Q3 		$2.39M Sell
23,400
-19,488
-45% -$1.62M 0.31% 70
2024
Q2 		$3.25M Sell
42,888
-4,920
-10% -$350K 0.44% 64
2024
Q1 		$3.59M Sell
47,808
-12,059
-20% -$960K 0.44% 68
2023
Q4 		$4.41M Buy
+59,867
New +$3.7M 0.62% 51

Other funds holding NUVL

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Parkman Healthcare Partners's NUVL Position: Q1 2026 in Review

Parkman Healthcare Partners reduced its Nuvalent (NUVL) stake by 26% in Q1 2026, selling an estimated $3.12M and leaving 88,078 shares worth $9.02M. The position accounts for 0.93% of the portfolio, ranked #38.

Parkman Healthcare Partners first reported a position in NUVL in Q4 2023 and has held it in 10 quarters since. The position peaked at $11.9M in Q4 2025. 263 funds tracked by Wall St. Rank hold NUVL as of Q1 2026.

  • Parkman Healthcare Partners held 88,078 shares of Nuvalent worth $9.02M as of Q1 2026.
  • Parkman Healthcare Partners sold 30,634 Nuvalent shares in Q1 2026, an estimated $3.12M.
  • Nuvalent made up 0.93% of Parkman Healthcare Partners's portfolio in Q1 2026, its #38 holding.
  • Parkman Healthcare Partners first reported a position in Nuvalent in Q4 2023 and has held it in 10 quarters since.
  • Parkman Healthcare Partners's Nuvalent position peaked at $11.9M in Q4 2025.
  • 263 funds tracked by Wall St. Rank held Nuvalent as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.